These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 15270646)

  • 1. Current status of the Arilvax; yellow fever vaccine.
    Barrett AD
    Expert Rev Vaccines; 2004 Aug; 3(4):413-20. PubMed ID: 15270646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time for a new yellow fever vaccine?
    Hayes EB
    Vaccine; 2010 Nov; 28(51):8073-6. PubMed ID: 20971115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inactivated cell-culture vaccine against yellow fever.
    Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
    N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arilvax (PowderJect).
    Barrett AD
    Curr Opin Investig Drugs; 2002 Jul; 3(7):992-5. PubMed ID: 12186277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice.
    Wilder-Smith A; Hill DR; Freedman DO
    Am J Trop Med Hyg; 2008 Mar; 78(3):359-60. PubMed ID: 18337324
    [No Abstract]   [Full Text] [Related]  

  • 15. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine.
    Ferguson M; Heath A
    Biologicals; 2004 Dec; 32(4):195-205. PubMed ID: 15572101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
    Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
    Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.